A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...